But camizestrant’s use could depend on uptake of monitoring – for now.

Any hopes of differentiation could come down to side effects.

Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.

Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.

Golcadomide will begin a new pivotal trial in follicular lymphoma.

The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.

The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.

In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.